Andrew W Walter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/312650/publications.pdf

Version: 2024-02-01

	1478505	1372567
668	6	10
citations	h-index	g-index
15	15	1910
docs citations	times ranked	citing authors
	citations 15	668 6 citations h-index 15 15

#	Article	IF	CITATIONS
1	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	10.7	307
2	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	27.8	266
3	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
4	Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e196-e206.	10.7	24
5	Constitutional mismatch repair deficiency presenting in childhood as three simultaneous malignancies. Pediatric Blood and Cancer, 2013, 60, E135-E136.	1.5	11
6	Brain tumors in children. Current Oncology Reports, 2004, 6, 438-444.	4.0	9
7	Larotrectinib imaging response in lowâ€grade glioma. Pediatric Blood and Cancer, 2020, 67, e28002.	1.5	5
8	Bone marrow transplant and pediatric multiple myeloma. Pediatric Blood and Cancer, 2019, 66, e27528.	1.5	3
9	MBCL-18. CHEK2 MUTATION IN HIGH-RISK MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i120-i120.	1.2	2
10	Medulloblastoma and secondary acute myeloid leukemia in a patient with Turner syndrome. Pediatric Blood and Cancer, 2019, 66, e27576.	1.5	1
11	CRAN-18. CASE SERIES OF INTRACRANIAL NON-GERMINOMATOUS GERM CELL TUMOR: A SINGLE INSTITUTION EXPERIENCE. Neuro-Oncology, 2018, 20, i40-i40.	1.2	0
12	PATH-56. CHEK2 MUTATION IN HIGH-RISK MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, vi170-vi171.	1,2	0
13	RARE-30. CASE SERIES OF INTRACRANIAL NON-GERMINOMATOUS GERM CELL TUMOR: A SINGLE INSTITUTION EXPERIENCE. Neuro-Oncology, 2018, 20, vi242-vi242.	1.2	0
14	PATH-30. TARGETED THERAPIES FOR PEDIATRIC LOW-GRADE GLIOMAS: A CASE SERIES. Neuro-Oncology, 2019, 21, vi149-vi149.	1.2	0
15	LGG-12. SAFETY AND EFFICACY OF DUAL THERAPY WITH DABRAFENIB AND TRAMETINIB IN AN INFANT WITH BRAF V600E MUTANT INOPERABLE LOW GRADE GLIOMA. Neuro-Oncology, 2021, 23, i34-i34.	1.2	0